Trial Profile
A Double-Blind, Placebo-Controlled, Randomised, Parallel Group Phase IIa Study to Evaluate the Histological Changes, Cellularity, Clinical Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Apr 2014
Price :
$35
*
At a glance
- Drugs AZD 1981 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 17 Mar 2012 Actual end date changed from Jun 2009 to Jan 2010 as reported by European Clinical Trials Database.
- 17 Mar 2012 Planned number of patients changed from 40 to 55 as reported by European Clinical Trials Database.
- 26 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.